Population pharmacokinetic model for adherence evaluation using lamivudine concentration monitoring

Therapeutic Drug Monitoring

Volumn 34, Issue 4, 2012, Pages 481-484

  Zhang, Chao ^a   Denti, Paolo ^a   Van Der Walt, Jan Stefan ^a   Ren, Yuan ^a   Smith, Peter ^a   Karlsson, Mats O ^b   McIlleron, Helen ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

lamivudine; NONMEM; population pharmacokinetics

Indexed keywords

LAMIVUDINE; LOPINAVIR PLUS RITONAVIR;

ALLOMETRY; ARTICLE; BODY WEIGHT; CHILD; COMPARTMENT MODEL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MONITORING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; STEADY STATE;

ABSORPTION; ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; AREA UNDER CURVE; CHILD, PRESCHOOL; HIV INFECTIONS; HUMANS; INFANT; LAMIVUDINE; MODELS, BIOLOGICAL;

EID: 84863838354     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31825c6067     Document Type: Article

References (14)

1. World Health Organization. Antiretroviral Therapy of HIV Infection in Infants and Children: Towards Universal Access: Recommendations for a Public Health Approach-2010 Revision. Geneva, Switzerland: World Health Organization; 2010. Available at: http://www.who.int/hiv/pub/paediatric/infants2010/en/index. html. Accessed July 13, 2010.
2. Johnson MA, Moore GJ, Yuen J, et al. Clinical pharmacokinetics of lamivudine. Clin Pharmacokinet. 1999;36:41-66. (Pubitemid 29056000)
3. Ren Y, Nuttall JJ, Egbers C, et al. Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis. J Acquir Immune Defic Syndr. 2008;47:566-569. (Pubitemid 351442016)
4. McIlleron H, Ren Y, Nuttall J, et al. Lopinavir exposure is insufficient in children given double doses of lopinavir/ritonavir during rifampicinbased treatment for tuberculosis. Antivir Ther. 2011;16:417-421.
5. Kenney KB, Wring SA, Carr RM, et al. Simultaneous determination of zidovudine and lamivudine in human serum using HPLC with tandem mass spectrometry. J Pharm Biomed Anal. 2000;22:967-983. (Pubitemid 30254330)
6. Beal S, Sheiner L, Boeckmann A. NONMEM Users Guides. Ellicott City, MD: ICON Development Solutions; 1989-2006.
7. Savic RM, Jonker DM, Kerbusch T, et al. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn. 2007;34:711-726. (Pubitemid 47477040)
8. Karlsson MO, Sheiner LB. The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm. 1993;21:735-750. (Pubitemid 24052760)
9. Anderson BJ, Holford NH. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet. 2009;24:25-36.
10. World Health Organization. Child growth standards: weight-for-age charts. Available at: http://www.who.int/childgrowth/standards/weight-for-age/en/index. html. Accessed July 13, 2010.
11. Bouazza N, Hirt D, Blanche S, et al. Developmental pharmacokinetics of lamivudine in 580 pediatric patients ranging from neonates to adolescents. Antimicrob Agents Chemother. 2011;55:3498-3504.
12. Tremoulet AH, Capparelli EV, Patel P, et al. Population pharmacokinetics of lamivudine in human immunodeficiency virus-exposed and -infected infants. Antimicrob Agents Chemother. 2007;51:4297-4302. (Pubitemid 350209880)
13. L'homme RF, Desire K, Ewings FM, et al. Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixeddose combination tablets. AIDS. 2008;22:557-565.
14. Moore KH, Yuen GJ, Raasch RH, et al. Pharmacokinetics of lamivudine administrated alone and with trimethoprim-sulfamethoxazole. Clin Pharmcol Ther. 1996;59:550-558.